Clinical Practice Guidelines for Hypophosphatasia

Area of Science:

• Genetics and Endocrinology
• Metabolic Bone Diseases

Background:

• Hypophosphatasia (HPP) is a rare inherited disorder caused by mutations in the ALPL gene, affecting tissue-nonspecific alkaline phosphatase (TNSALP) activity.
• Clinical manifestations of HPP vary widely, necessitating standardized diagnostic and management approaches.
• Recent advancements in enzyme replacement therapy have improved outcomes for severe HPP cases.

Purpose of the Study:

• To establish evidence-based clinical practice guidelines for Hypophosphatasia (HPP).
• To provide physicians with standardized recommendations for HPP diagnosis and management.
• To support clinical decision-making for patients with HPP.

Main Methods:

• A task force formulated 21 clinical questions covering HPP diagnosis and management.
• A systematic literature search was conducted using PubMed/MEDLINE to gather evidence.
• Recommendations were developed based on the literature search and refined through expert review and public comment.

Main Results:

• The guidelines address clinical manifestations, diagnosis, management, and treatment of HPP.
• Evidence-based recommendations were formulated for 21 distinct clinical questions.
• The guidelines were developed through a rigorous process involving a task force, literature review, and expert consensus.

Conclusions:

• These clinical practice guidelines provide a standardized framework for HPP care.
• The guidelines aim to improve the quality of medical care for HPP patients.
• Regular revision and updates are anticipated to incorporate future advancements in HPP management.